Gilead Sciences Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (411)

Latest Posts

About This Stock More About This Stock
Gilead Is Persona Non Grata
Article By: Shock Exchange
Wednesday, November 1, 2017 11:19 AM EST
GILD's HCV revenue fell 28% Q/Q. Additional competition might have hastened its demise. Total revenue was off 9%. Yescarta is exciting but it will not be able to replace the HCV run-off and it will not kick in until 2018.
In this article: GILD Also: CELG, ABBV
Read
3 ETFs To Watch On Biotech Earnings
Article By: Zacks Investment Research
Sunday, October 29, 2017 5:13 PM EST
The earnings season is off to a flying start with equity markets. However, the performance has been a mixed bag for biotech companies with some beating market expectations, while a few failed to do so.
In this article: ALXN, AMGN, BIIB, BIB, IBB, BBH, GILD
Read
Gilead Q3 Earnings And Revenues Sink
Article By: Zacks Investment Research
Friday, October 27, 2017 3:56 AM EST
Gilead Sciences, Inc. released its third-quarter 2017 financial results, posting earnings of $2.06 per share and revenues of $6.51 billion.
In this article: GILD
Read
Here's What's Has Happened In The HCV Space Lately
Article By: Zacks Investment Research
Sunday, October 8, 2017 6:08 PM EST
It is not a surprise that quite a few pharma and biotech companies are working on bringing new, improved, shorter-duration hepatitis C virus (HCV) treatments to the market. The market is thus getting crowded and seeing increased pricing pressure.
In this article: JNJ, GILD, ABBV, MRK Also: BMY
Read
Week In Review: Another Billion Dollar Week For China Life Science Deals
Article By: ChinaBio® Today
Saturday, September 30, 2017 5:55 PM EST
Shanghai Pharma Holding (SHA: 601607) may acquire part of Alvogen -- possibly Alvogen's US operations -- according to Bloomberg. Alvogen is a US-based generic drug maker thought to be worth as much as $4 billion.
In this article: NVO, SNY, SVA, AMGN, GILD, ZLAB, TSRO
Read

PARTNER HEADLINES

Latest Tweets for $GILD

No tweets yet!

$GILD

Gilead Crohn's Treatment Is Not The Solution To GLD Revenue Issues
Kurt Benson 3/24/2017 10:12:59 PM

I have to agree with your assessment on $GILD. Do you know anything about $VBIO? I read a promising article here about their having a major breakthrough in #Crohn's research.

www.talkmarkets.com/.../interview-with-vitality-biopharma-inc

Not a lot of info on the company though.

Gilead Crohn's Treatment Is Not The Solution To GLD Revenue Issues
Kirk Sheffield 3/24/2017 10:11:55 PM

I think $GILD will rebound. This isn't the only product they have in their pipeline.

Gilead Crohn's Treatment Is Not The Solution To GLD Revenue Issues
Alpha Stockman 3/24/2017 10:07:45 PM

I've been rather disappointed with #Gilead myself. After reading your article, I'm planning to offload some $GILD.

Gilead Sciences Receives Canadian Approval For HIV Drug
David Reynolds 2/20/2017 10:04:11 PM

The opening up of this market for #GileadSciences should bode well for the stock $GILD.

Gilead Sciences: Cheap Growth Or Value Trap?
Karen Klein 9/13/2016 5:39:48 PM

Excellent analysis, you have effectively convinced me to change my position on #Gilead. $GILD

3 Cult Stocks To Avoid In 2015
Bruce Powers 1/26/2015 8:01:06 AM

Great article and glad to read the reasoning to consider $GILD as a safer investment short, mid and long term.

3 Cult Stocks To Avoid In 2015
BreakingBad News 1/25/2015 6:09:51 PM

Sorry all, thanks for the clarification. My bad! Now that I've read it through, it all makes total sense. $GILD, $BAC, $WFM, and $VA are my plays for 2015.

3 Cult Stocks To Avoid In 2015
BreakingBad News 1/25/2015 4:48:08 PM

I'd say this is a minority view, I've seen several others stating that $GILD was a stock to buy this year.

1 to 8 of 8 comments